<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411229</url>
  </required_header>
  <id_info>
    <org_study_id>L_9570</org_study_id>
    <secondary_id>M017527</secondary_id>
    <nct_id>NCT00411229</nct_id>
  </id_info>
  <brief_title>Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer</brief_title>
  <acronym>CLASSIC</acronym>
  <official_title>A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary:&#xD;
&#xD;
        -  To demonstrate that capecitabine/oxaliplatin as adjuvant chemotherapy is superior to&#xD;
           observation alone in terms of 3 year disease-free survival (DFS) rate in&#xD;
           chemotherapy-naïve patients who underwent potentially curative resection for gastric&#xD;
           cancer.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  To compare the overall survival of surgery and capecitabine/ oxaliplatin as adjuvant&#xD;
           therapy versus surgery alone. To evaluate the safety profile of capecitabine/oxaliplatin&#xD;
           adjuvant therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of the original cancer</measure>
    <time_frame>From the beginning to end of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of a new gastric cancer</measure>
    <time_frame>From beginning to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death due to any cause</measure>
    <time_frame>From the beginning to the end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From beginning to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>From beginning to end of study</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1035</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine + Oxalipatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>IV infusion, 130mg/m²</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory patients&#xD;
&#xD;
          -  Karnofsky performance status of ≥70 %.&#xD;
&#xD;
          -  Histologically confirmed gastric adenocarcinoma, staged pathologically, stage II&#xD;
             (T2N1, T1N2, T3N0), IIIa (T3N1, T2N2, T4N0), and IIIb (T3N2). At least 15 examined&#xD;
             lymph nodes are required to ensure the adequate TNM (Tumor Nodes Metastases&#xD;
             classification.&#xD;
&#xD;
          -  Patients who underwent curative D2 lymphadenectomy resection for gastric cancer with&#xD;
             no macroscopic or microscopic evidence for remaining tumor, who can be randomized to&#xD;
             either study arm within 6 weeks after surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Women of childbearing potential with either a positive or no pregnancy test at&#xD;
             baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be&#xD;
             considered of non-child bearing potential.&#xD;
&#xD;
          -  Sexually active males and females (of childbearing potential) unwilling to practice&#xD;
             contraception during the study.&#xD;
&#xD;
          -  Any evidence of metastatic disease (including presence of tumor cells in the ascites).&#xD;
&#xD;
          -  Previous cytotoxic chemotherapy, radiotherapy or immunotherapy except corticosteroids,&#xD;
             for the currently treated gastric cancer.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to study treatment start, or lack of complete&#xD;
             recovery from the effects of major surgery.&#xD;
&#xD;
          -  History of another malignancy within the last five years except cured basal cell&#xD;
             carcinoma of skin and cured carcinoma in-situ of uterine cervix.&#xD;
&#xD;
          -  Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery&#xD;
             disease, New York Heart Association (NYHA) grade II or greater congestive heart&#xD;
             failure or serious cardiac arrhythmia requiring medication or myocardial infarction&#xD;
             within the last 12 months.&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract or those who have&#xD;
             malabsorption syndrome likely to influence absorption of capecitabine, or inability to&#xD;
             take oral medication.&#xD;
&#xD;
          -  Known peripheral neuropathy ≥ CTCAEv3 grade 1 (Common Terminology for Adverse Events).&#xD;
             Absence of deep tendon reflexes as the sole neurologic abnormality does not render the&#xD;
             patient ineligible.&#xD;
&#xD;
          -  Organ allografts requiring immunosuppressive therapy.&#xD;
&#xD;
          -  Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant&#xD;
             disease.&#xD;
&#xD;
          -  Moderate or severe renal impairment [creatinine clearance equal to or below 50 ml/min&#xD;
             (calculated according to Cockroft and Gault)], or serum creatinine &gt; 1.5 x upper limit&#xD;
             of normal (ULN).&#xD;
&#xD;
          -  Any of the following laboratory values:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count &lt; 100 x 109/L&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
               -  ALAT, ASAT &gt; 2.5 x ULN&#xD;
&#xD;
               -  Alkaline phosphatase &gt; 2.5 x ULN.&#xD;
&#xD;
          -  Prior unanticipated severe reaction to fluoropyrimidine therapy (with or without&#xD;
             documented dihydropyrimidine dehydrogenase (DPD) deficiency) or patients with known&#xD;
             DPD deficiency.&#xD;
&#xD;
          -  Hypersensitivity to platinum compounds or any of the components of the study&#xD;
             medications.&#xD;
&#xD;
          -  Received any investigational drug or agent/procedure, i.e. participation in another&#xD;
             trial, within 4 weeks before randomization.&#xD;
&#xD;
          -  Blood transfusions or growth factors to aid hematologic recovery within 2 weeks prior&#xD;
             to study treatment start.&#xD;
&#xD;
          -  Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or&#xD;
             chemically related analogues, such as brivudine.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>December 12, 2006</study_first_submitted>
  <study_first_submitted_qc>December 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2006</study_first_posted>
  <last_update_submitted>February 18, 2013</last_update_submitted>
  <last_update_submitted_qc>February 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

